Cytokine traps: multi-component, high-affinity blockers of cytokine action
Aris N. Economides(Regeneron (United States)), Neil Stahl(Arthritis and Rheumatism Associates), Thomas J. Daly(Regeneron (United States)), Vivien Wong(Regeneron (United States)), Laura Rocco Carpenter(Regeneron (United States)), Jennifer McNay(Regeneron (United States)), Scott Carver(University of Tasmania), James P. Fandl(Regeneron (United States)), Renta Hutabarat(Alnylam Pharmaceuticals (United States)), Swayampakula Ramakanth(Regeneron (United States)), Erica Pyles(Regeneron (United States)), George D. Yancopoulos(Regeneron (United States)), Xiaobing Xu(Jiangsu Province Hospital), Frank Lee(Regeneron (United States)), Kevin M. Bailey(NOAA National Marine Fisheries Service Alaska Fisheries Science Center), Michael Young(Regeneron (United States)), Czeslaw Radziejewski(Regeneron (United States)), John S. Rudge(Regeneron (United States)), Christopher Hartnett(Regeneron (United States)), Ellen Koehler-Stec(Regeneron (United States)), Tammy Huang(Regeneron (United States))
Cited by 361
Related Papers
Vascular-specific growth factors and blood vessel formation
|Nature|2000|3.7k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
VEGF-Trap: A VEGF blocker with potent antitumor effects
|Proceedings of the National Academy of Sciences|2002|1.7k
Regulation of the Germinal Center Response by MicroRNA-155
|Science|2007|1.5k
Angiopoietin-1 protects the adult vasculature against plasma leakage
|Nature Medicine|2000|1.3k